Miflonid Breezhaler (Budesonide)

Budesonide binds to glucocorticoid receptors inside airway cells, altering gene expression to suppress the production of inflammatory mediators such as cytokines and chemokines. This reduces swelling, mucus production, and immune‑cell infiltration, leading to less airway narrowing and improved airflow.

The dose of Miflonid Breezhaler is individualized by a qualified prescriber based on the severity of the patient’s asthma or COPD, age, and response to therapy. The prescribing clinician determines the number of inhalations per day and any necessary adjustments over time.

Safety data for budesonide inhalation during pregnancy and lactation are limited. The product should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss use with their healthcare provider.

To request Miflonid Breezhaler, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and the necessary import documentation.

Miflonid Breezhaler delivers budesonide, which has a high topical potency and low systemic bioavailability, similar to other inhaled corticosteroids such as fluticasone propionate. Differences lie mainly in device design, particle size distribution, and specific pharmacokinetic profiles, which can affect patient preference and adherence.

Store the Breezhaler device and its inhalation powder at ambient temperature, preferably below 25 °C. Keep it in the original packaging, protect it from moisture, heat, and direct sunlight. Do not expose the inhaler to freezing conditions, and ensure the device is kept out of reach of children.

The patient removes a capsule from the Breezhaler device, inserts it, and inhales through the mouthpiece with a steady, deep breath. After inhalation, the patient should hold their breath for about 10 seconds, then rinse the mouth with water and spit to reduce the risk of oral candidiasis.

Serious risks include paradoxical bronchospasm, adrenal suppression with prolonged high‑dose use, and severe allergic reactions such as anaphylaxis or angioedema. Patients should be instructed to seek immediate medical attention if they experience sudden worsening of breathing, severe swelling, or signs of systemic corticosteroid excess.

Miflonid Breezhaler is contraindicated in individuals with a known hypersensitivity to budesonide or any component of the inhaler device. It should also be avoided in patients with untreated active infections of the respiratory tract until the infection is resolved, and in those for whom systemic corticosteroid therapy is contraindicated.